ace1702
HER2-positive Metastatic Breast Cancer
Acepodia Biotech, Inc.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
188 Active assets in the HER2-positive Metastatic Breast Cancer cohort.
View all 50 →
Same molecule, other indications
ace1702 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →